ATE548368T1 - Harnstoffderivate, verfahren zu ihrer herstellung und ihre anwendungen - Google Patents

Harnstoffderivate, verfahren zu ihrer herstellung und ihre anwendungen

Info

Publication number
ATE548368T1
ATE548368T1 AT06724709T AT06724709T ATE548368T1 AT E548368 T1 ATE548368 T1 AT E548368T1 AT 06724709 T AT06724709 T AT 06724709T AT 06724709 T AT06724709 T AT 06724709T AT E548368 T1 ATE548368 T1 AT E548368T1
Authority
AT
Austria
Prior art keywords
applications
production
urea derivatives
urea
derivatives
Prior art date
Application number
AT06724709T
Other languages
English (en)
Inventor
Pierre Deprez
Helene Jary
Taoues Temal
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Application granted granted Critical
Publication of ATE548368T1 publication Critical patent/ATE548368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treating Waste Gases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06724709T 2005-04-29 2006-04-24 Harnstoffderivate, verfahren zu ihrer herstellung und ihre anwendungen ATE548368T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504360A FR2885129B1 (fr) 2005-04-29 2005-04-29 Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
PCT/EP2006/004166 WO2006117211A2 (en) 2005-04-29 2006-04-24 Urea derivatives methods for their manufacture and uses thereof

Publications (1)

Publication Number Publication Date
ATE548368T1 true ATE548368T1 (de) 2012-03-15

Family

ID=35311522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724709T ATE548368T1 (de) 2005-04-29 2006-04-24 Harnstoffderivate, verfahren zu ihrer herstellung und ihre anwendungen

Country Status (25)

Country Link
US (2) US8247412B2 (de)
EP (2) EP2354137A1 (de)
JP (1) JP4995189B2 (de)
KR (1) KR20080003380A (de)
CN (1) CN101238120A (de)
AR (1) AR056991A1 (de)
AT (1) ATE548368T1 (de)
AU (1) AU2006243328B2 (de)
BR (1) BRPI0611025A2 (de)
CA (1) CA2605008A1 (de)
CR (1) CR9469A (de)
CY (1) CY1112960T1 (de)
DK (1) DK1874765T3 (de)
EA (1) EA200702375A1 (de)
ES (1) ES2384052T3 (de)
FR (1) FR2885129B1 (de)
HR (1) HRP20120424T1 (de)
IL (1) IL186854A0 (de)
NO (1) NO20076145L (de)
PL (1) PL1874765T3 (de)
PT (1) PT1874765E (de)
TW (1) TW200714598A (de)
UY (1) UY29510A1 (de)
WO (1) WO2006117211A2 (de)
ZA (1) ZA200708871B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
ATE450262T1 (de) * 2005-11-25 2009-12-15 Galapagos Sas Harnstoff-derivate als calcium-rezeptor- modulatoren
EP2010150A2 (de) * 2006-04-20 2009-01-07 Amgen Inc. Stabile emulsionsformulierungen
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
ES2499015T3 (es) * 2007-05-08 2014-09-26 Ajinomoto Co., Inc. Agente profiláctico o terapéutico para la diarrea
CA2692598A1 (en) * 2007-07-10 2009-01-15 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
WO2019222393A1 (en) * 2018-05-15 2019-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotective compositions and methods of using the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897242A (en) 1968-02-13 1975-07-29 Ciba Geigy Ag Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops
IL31574A0 (en) 1968-02-13 1969-04-30 Ciba Ltd Use of certain ureas for combating weeds
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4521583A (en) 1984-02-09 1985-06-04 American Cyanamid Company Curable epoxy resin compositions
US4594373A (en) 1984-02-09 1986-06-10 American Cyanamid Company Curable epoxy resin compositions
FR2601363B1 (fr) * 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5227397A (en) 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
EP0597830A1 (de) 1989-07-03 1994-05-25 New York University Nyu Medical Center Verwendung von Polyaminen als die Ionenkanäle regulierenden Wirkstoffe
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
ATE196759T1 (de) 1990-11-19 2000-10-15 Monsanto Co Inhibitoren retroviraler proteasen
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0641333B1 (de) 1992-05-20 1996-08-14 G.D. Searle & Co. Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
KR100376150B1 (ko) 1994-11-04 2003-11-01 산텐 세이야꾸 가부시키가이샤 히드록시기를함유하는1,3-디알킬우레아유도체
DE69528197T2 (de) 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
JP3306571B2 (ja) 1995-06-28 2002-07-24 参天製薬株式会社 エンドセリン変換酵素阻害剤
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
DE69733649T2 (de) 1996-04-09 2006-05-18 NPS Pharmaceuticals, Inc., Salt Lake City Calcylitische verbindungen
EP1019367A1 (de) 1997-08-05 2000-07-19 Novo Nordisk A/S Derivate von 2,5- und 3,5-disubstituierten anilinen, ihre herstellung und verwendung
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
WO1999037604A2 (en) 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
EP1169038B9 (de) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclische protein-tyrosinkinasehemmer
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6598746B2 (en) * 2001-09-13 2003-07-29 Washburn Graphics, Inc. Display carton having an internally reinforced hanger panel
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
JP2005336173A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 骨粗鬆症治療剤
ES2561111T3 (es) 2004-05-28 2016-02-24 Mitsubishi Tanabe Pharma Corporation Arilalquilaminas y procedimiento para la producción de las mismas
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US7585886B2 (en) 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
ATE450262T1 (de) 2005-11-25 2009-12-15 Galapagos Sas Harnstoff-derivate als calcium-rezeptor- modulatoren
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
CA2692598A1 (en) 2007-07-10 2009-01-15 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Also Published As

Publication number Publication date
ES2384052T3 (es) 2012-06-28
EP2354137A1 (de) 2011-08-10
TW200714598A (en) 2007-04-16
CN101238120A (zh) 2008-08-06
PL1874765T3 (pl) 2012-08-31
WO2006117211A2 (en) 2006-11-09
WO2006117211A3 (en) 2007-01-11
AR056991A1 (es) 2007-11-07
ZA200708871B (en) 2009-03-25
FR2885129B1 (fr) 2007-06-15
JP2008539186A (ja) 2008-11-13
EA200702375A1 (ru) 2008-06-30
US20100240889A1 (en) 2010-09-23
US8247412B2 (en) 2012-08-21
JP4995189B2 (ja) 2012-08-08
FR2885129A1 (fr) 2006-11-03
UY29510A1 (es) 2006-12-29
HRP20120424T1 (hr) 2012-06-30
PT1874765E (pt) 2012-05-25
EP1874765A2 (de) 2008-01-09
KR20080003380A (ko) 2008-01-07
IL186854A0 (en) 2008-02-09
AU2006243328B2 (en) 2011-09-08
DK1874765T3 (da) 2012-06-18
CA2605008A1 (en) 2006-11-09
EP1874765B1 (de) 2012-03-07
CR9469A (es) 2008-03-06
NO20076145L (no) 2008-01-28
US20120283255A1 (en) 2012-11-08
AU2006243328A1 (en) 2006-11-09
CY1112960T1 (el) 2016-04-13
BRPI0611025A2 (pt) 2016-11-16

Similar Documents

Publication Publication Date Title
EP1894626A4 (de) Homogener, hochdisperser metallkatalysator und verfahren zu seiner herstellung
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
ATE381564T1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE602006004379D1 (de) Nanodraht-Struktur und Verfahren zu ihrer Herstellung
DE602006012666D1 (de) Ren eignen und verfahren zu deren herstellung
DE602006014165D1 (de) Eine fluorsulfonylgruppe enthaltende verbindung, verfahren zu deren herstellung und polymer davon
DE502005007840D1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE602006012283D1 (de) Integrierte schaltung und verfahren zu ihrer herstellung
IL185804A0 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE554772T1 (de) Pteridine als hcv-hemmer und verfahren zu ihrer herstellung
EP1921674A4 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE549332T1 (de) Zyklische pyridyl-n-(1,3,4)-thiadiazol-2-yl- benzol-sulfonamide, verfahren für ihre herstellung und anwendung als pharmaka
ATE505469T1 (de) 7-alkynyl-1,8-naphthyridon-derivate, verfahren zu ihrer herstellung und ihre verwendung für therapeutika
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ZA200708871B (en) Urea derivatives methods for their manufacture and uses thereof
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
BRPI0720530A2 (pt) Partícula, processo para preparar a partícular, e, composição
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE602006021029D1 (de) Filtermodul und verfahren zu dessen herstellung
DE502007001726D1 (de) Elastische Einlage, Verfahren zu deren Herstellung und Verwendung
DE502007002958D1 (de) Armierte supraleitende wicklung und verfahren zu deren herstellung
DE602005026176D1 (de) Rollenlose spule und verfahren zu ihrer herstellung
DE502006009351D1 (de) Feinteiliges azopigment und verfahren zu seiner herstellung